
This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.

This article estimates the comprehensive value of direct-acting antivirals for the treatment of hepatitis C virus using a generalized cost-effectiveness analysis.

New value frameworks should incorporate real-world evidence that reflects patient treatment behavior, adherence to medication, and equity concerns arising from disparities in care.

Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.

Published: December 5th 2023 | Updated:

Published: June 15th 2016 | Updated:

Published: November 13th 2018 | Updated:

259 Prospect Plains Rd, Bldg H
 Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
